Skip to main content
. 2019 Jun 18;11(6):840. doi: 10.3390/cancers11060840

Figure 4.

Figure 4

RNF128 promoted the activation of the EGFR/ERK/MMP-2 pathway. RNF128-overexpression cells were pretreated with gefitinib (1 µM), PD98059 (10 µM), or MMP-2 inhibitor (1 µM) for 24 h. (AC) Western blot analysis of the expression levels of EGFR, p-EGFR, ERK, p-ERK, MEK, p-MEK, and MMP-2. Cell invasion (D) and migration (E) were evaluated after treatment for 24 h. Magnification for (D): ×40, magnification for (E): ×40.